| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.92 [0.76, 1.12] | | < 1 | | 0% | 1 study (1/-) | 80.0 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 0.81 [0.67, 0.97] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | important | - |
| DCR | 1.39 [0.92, 2.09] | | > 1 | | 0% | 1 study (1/-) | 94.0 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 4.35 [1.00, 19.05] | | > 1 | | 0% | 1 study (1/-) | 97.4 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| TRAE (grade 3-4) | 1.74 [1.22, 2.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 1.50 [0.76, 2.95] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.57 [0.19, 1.73] | | < 1 | | 0% | 1 study (1/-) | 83.9 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 3.00 [0.15, 60.20] | | < 1 | | 0% | 1 study (1/-) | 23.9 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 1.68 [0.46, 6.16] | | < 1 | | 0% | 1 study (1/-) | 21.9 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Arthritis TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 1.50 [0.40, 5.62] | | < 1 | | 0% | 1 study (1/-) | 27.2 % | NA | not evaluable | | non important | - |
| Back pain (TRAE grade 3-4) | 0.08 [0.00, 1.64] | | < 1 | | 0% | 1 study (1/-) | 94.7 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 25.42 [1.54, 420.53] | | < 1 | | 0% | 1 study (1/-) | 1.3 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.25 [0.02, 2.74] | | < 1 | | 0% | 1 study (1/-) | 87.1 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 0.25 [0.01, 7.42] | | < 1 | | 0% | 1 study (1/-) | 78.6 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 2.01 [0.42, 9.56] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 33.86 [4.65, 246.49] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.25 [0.01, 7.42] | | < 1 | | 0% | 1 study (1/-) | 78.6 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.58 [0.33, 1.02] | | < 1 | | 0% | 1 study (1/-) | 97.1 % | NA | not evaluable | | non important | - |
| Epistaxis TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.49 [0.14, 1.72] | | < 1 | | 0% | 1 study (1/-) | 86.7 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 3.00 [0.15, 60.20] | | < 1 | | 0% | 1 study (1/-) | 23.9 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.75 [0.36, 8.53] | | < 1 | | 0% | 1 study (1/-) | 24.4 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.85 [0.51, 6.71] | | < 1 | | 0% | 1 study (1/-) | 17.6 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 1.99 [0.09, 44.45] | | < 1 | | 0% | 1 study (1/-) | 33.3 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 2.00 [0.22, 18.02] | | < 1 | | 0% | 1 study (1/-) | 27.0 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.99 [0.18, 5.48] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.25 [0.01, 7.42] | | < 1 | | 0% | 1 study (1/-) | 78.6 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.99 [0.09, 44.45] | | < 1 | | 0% | 1 study (1/-) | 33.3 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 0.89 [0.29, 2.70] | | < 1 | | 0% | 1 study (1/-) | 57.9 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 3.00 [0.15, 60.20] | | < 1 | | 0% | 1 study (1/-) | 23.9 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 3.00 [0.15, 60.20] | | < 1 | | 0% | 1 study (1/-) | 23.9 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 1.99 [0.09, 44.45] | | < 1 | | 0% | 1 study (1/-) | 33.3 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 3.02 [0.36, 25.23] | | < 1 | | 0% | 1 study (1/-) | 15.6 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.99 [0.03, 29.79] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.50 [0.15, 14.48] | | < 1 | | 0% | 1 study (1/-) | 36.5 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.87 [0.25, 3.00] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.99 [0.09, 11.04] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
